Heart Disease Home > Dabigatran Therapy

Dabigatran etexilate mesylate (Pradaxa®) is a medication prescribed to prevent blood clots and strokes in people who have atrial fibrillation, a type of irregular heart rhythm (arrhythmia). It is also approved to treat blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolisms) and to prevent them from recurring.
People undergoing therapy with dabigatran should be aware of the warnings and precautions associated with this medication before beginning treatment. For example, because this medication is a type of "blood thinner," it can increase the risk for potentially dangerous bleeding problems.
Although dabigatran has possible risks, clinical studies have shown that this medication requires less monitoring and is more effective than warfarin (Coumadin®, Jantoven®), another blood thinner used to treat atrial fibrillation.
(For more information on this atrial fibrillation therapy, click Dabigatran. This article provides a complete overview of the drug, including information on how it works, general precautions, and potential side effects.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):



Related Channels

eMedTV Links
Copyright © 2006-2018 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.